MARKET

VIRX

VIRX

Viracta Therapeutics Inc
NASDAQ
4.310
+0.220
+5.38%
Opening 14:51 09/30 EDT
OPEN
4.040
PREV CLOSE
4.090
HIGH
4.400
LOW
4.040
VOLUME
73.65K
TURNOVER
296.46K
52 WEEK HIGH
8.16
52 WEEK LOW
1.820
MARKET CAP
161.88M
P/E (TTM)
-3.4017
1D
5D
1M
3M
1Y
5Y
Viracta Therapeutics Announces New Employment Inducement Grant
SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that, in connection with the appointment of Mark Rothera as Viracta’s new Preside...
GlobeNewswire · 09/19 20:30
Viracta Therapeutics names Mark Rothera as new CEO
Viracta Therapeutics (NASDAQ:VIRX) on Monday appointed...
Seekingalpha · 09/19 13:14
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Benzinga · 09/07 21:45
Viracta Obtains Orphan Drug Status From European Commission For T-cell Lymphoma Candidate
The European Commission has granted an orphan drug designation (ODD) to Viracta’s (NASDAQ: VIRX) lead drug combination nanatinostat and valganciclovir (Nana-val) for the treatment of peripheral T-cell lymphoma (PTCL).
Benzinga · 09/07 14:16
Viracta Therapeutics gets European orphan drug designation for lymphoma combo treatment
Viracta Therapeutics (NASDAQ:VIRX) on Wednesday <a hre...
Seekingalpha · 09/07 13:35
BRIEF-Viracta Says European Commission Grants Orphan Drug Designation For Nana-val For Treatment Of Peripheral T-Cell Lymphoma
BRIEF-Viracta Says European Commission Grants Orphan Drug Designation For Nana-val For Treatment Of Peripheral T-Cell Lymphoma
Reuters · 09/07 13:25
Viracta Therapeutics Announces Orphan Drug Designation Granted By The European Commission For Nana-val For The Treatment Of Peripheral T-cell Lymphoma
First orphan drug designation granted for Nana-val by the European Commission; fifth globally
Benzinga · 09/07 13:01
Viracta Therapeutics' T-Cell Lymphoma Treatment Candidate Gets Orphan Drug Designation in Europe
Viracta Therapeutics' T-Cell Lymphoma Treatment Candidate Gets Orphan Drug Designation in Europe
MT Newswires · 09/07 11:08
More
About VIRX
Viracta Therapeutics, Inc. is a clinical-stage, precision oncology company. The Company is focused on advancing new medicines for the treatment of virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma. Its lead product candidate is an all-oral combination therapy of its investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including Phase II basket trial for the treatment of multiple subtypes of relapsed/refractory EBV+ lymphoma (NAVAL-1), as well as a Phase Ib/II trial for the treatment of EBV+ recurrent and other EBV+ solid tumors. The Company's product candidate pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor.

Webull offers kinds of Viracta Therapeutics Inc stock information, including NASDAQ:VIRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRX stock methods without spending real money on the virtual paper trading platform.